Literature DB >> 20562850

Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression.

Sofia Asioli1, Lori A Erickson, Alberto Righi, Long Jin, Marco Volante, Sarah Jenkins, Mauro Papotti, Gianni Bussolati, Ricardo V Lloyd.   

Abstract

The Turin Proposal algorithm defines poorly differentiated carcinoma on the basis of the presence of solid/trabecular/insular growth pattern, absence of conventional nuclear features of papillary carcinoma, and the presence of at least one of the following features: convoluted nuclei, mitotic activity > or =3/10 HPF, or tumor necrosis. IMP3 appears to have diagnostic and prognostic value in many solid tumors, including thyroid carcinomas. We examined a series of follicular-cell carcinomas with prominent solid patterns diagnosed at Mayo Clinic (56 cases) (Rochester, MN, USA) and at the University of Turin (96 cases) (Northern Italy) to validate the Turin consensus criteria defining poorly differentiated carcinoma of the thyroid and to evaluate the prevalence and prognostic behavior of this tumor. On this series, we analyzed the expression of conventional markers by immunohistochemistry and we investigated the expression of IMP3 by both immunohistochemistry and qRT-PCR. The prevalence of poorly differentiated carcinoma among the USA cases was 1.8% (56/3128) and that in the cases of Northern Italy was 6.7% (96/1442). Tumor characteristics were similar in the cases from the USA and from Italy except for extensive vascular invasion and a prevalent insular growth pattern (lower the former, higher the latter in the Italian series). In univariate analysis, the risk of death was higher for age > or =45, tumors > or =4 cm, and IMP3 positivity. Multivariate analysis showed that the risk of death from poorly differentiated carcinoma was higher for age > or =45. The Turin consensus criteria can reliably select poorly differentiated carcinomas. Tumors from the USA and from Italy showed similar overall survival, although the prevalence of poorly differentiated carcinoma was higher in Northern Italy. Expression of IMP3 appears to be an adverse prognostic factor for poorly differentiated thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20562850     DOI: 10.1038/modpathol.2010.117

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  47 in total

1.  THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer.

Authors:  Federica Panebianco; Lindsey M Kelly; Pengyuan Liu; Shan Zhong; Sanja Dacic; Xiaosong Wang; Aatur D Singhi; Rajiv Dhir; Simion I Chiosea; Shih-Fan Kuan; Rohit Bhargava; David Dabbs; Sumita Trivedi; Manoj Gandhi; Rachel Diaz; Abigail I Wald; Sally E Carty; Robert L Ferris; Adrian V Lee; Marina N Nikiforova; Yuri E Nikiforov
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-13       Impact factor: 11.205

2.  Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.

Authors:  Alyaksandr V Nikitski; Susan L Rominski; Vincenzo Condello; Cihan Kaya; Mamta Wankhede; Federica Panebianco; Hong Yang; Daniel L Altschuler; Yuri E Nikiforov
Journal:  Thyroid       Date:  2019-08-16       Impact factor: 6.568

3.  SEOM clinical guideline thyroid cancer (2019).

Authors:  E Gallardo; J Medina; J C Sánchez; A Viúdez; E Grande; I Porras; T Ramón Y Cajal; J Trigo; L Iglesias; J Capdevila
Journal:  Clin Transl Oncol       Date:  2020-01-31       Impact factor: 3.405

4.  Imp3 expression in benign and malignant thyroid tumors and hyperplastic nodules.

Authors:  Sezer Kulaçoğlu; Gamze Erkılınç
Journal:  Balkan Med J       Date:  2015-01-01       Impact factor: 2.021

Review 5.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 6.  Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes.

Authors:  Maryam Zarkesh; Azita Zadeh-Vakili; Fereidoun Azizi; Forough Foroughi; Maziar Mohammad Akhavan; Mehdi Hedayati
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

7.  Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies.

Authors:  F Pacini; F Basolo; R Bellantone; G Boni; M A Cannizzaro; M De Palma; C Durante; R Elisei; G Fadda; A Frasoldati; L Fugazzola; R Guglielmi; C P Lombardi; P Miccoli; E Papini; G Pellegriti; L Pezzullo; A Pontecorvi; M Salvatori; E Seregni; P Vitti
Journal:  J Endocrinol Invest       Date:  2018-05-04       Impact factor: 4.256

8.  Undetectable Thyroglobulin Levels in Poorly Differentiated Thyroid Carcinoma Patients Free of Macroscopic Disease After Initial Treatment: Are They Useful?

Authors:  Tihana Ibrahimpasic; Ronald Ghossein; Diane L Carlson; Iain J Nixon; Frank L Palmer; Snehal G Patel; Robert M Tuttle; Ashok Shaha; Jatin P Shah; Ian Ganly
Journal:  Ann Surg Oncol       Date:  2015-04-17       Impact factor: 5.344

9.  Follicular thyroid carcinoma presenting as a massive chest wall tumor.

Authors:  Ryan Gertz; Rakesh Sarda; Ricardo Lloyd
Journal:  Endocr Pathol       Date:  2013-03       Impact factor: 3.943

10.  Prognostic value of the IASLC/ATS/ERS classification and IMP3 expression in lung adenocarcinoma of Chinese cases.

Authors:  Xiangjie Sun; Ping Wei; Chen Shen; Yusi Yang; Yiqin Wang; Yuan Li; Xiang Du
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.